MedTrace Logo

The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

NCT00985933 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-05-04

No results posted yet for this study

Summary

The purpose of this study is to assess if ketamine will induce, in healthy volunteers, impairment of working memory and if the drug AZD8529 will block the effects of ketamine on working memory as assessed by functional magnetic resonance imaging (fMRI).

Conditions

  • Healthy
  • Memory Impairment

Interventions

DRUG

AZD8529

6 capsules by mouth 1 time 12 to 24 prior to assessments

DRUG

Placebo to match AZD8529

6 capsules by mouth 1 time 12 to 24 hours prior to assessments

Sponsors & Collaborators

Principal Investigators

  • John Krystal · Chair, Department of PsychiatryYale University School of MedicineChief of Psychiatry, Yale-New Haven Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00985933 on ClinicalTrials.gov